CRGX vs. QURE, AVXL, IMNM, GYRE, PHAT, VIR, CRON, REPL, PHAR, and XERS
Should you be buying CARGO Therapeutics stock or one of its competitors? The main competitors of CARGO Therapeutics include uniQure (QURE), Anavex Life Sciences (AVXL), Immunome (IMNM), Gyre Therapeutics (GYRE), Phathom Pharmaceuticals (PHAT), Vir Biotechnology (VIR), Cronos Group (CRON), Replimune Group (REPL), Pharming Group (PHAR), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry.
CARGO Therapeutics vs. Its Competitors
uniQure (NASDAQ:QURE) and CARGO Therapeutics (NASDAQ:CRGX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.
CARGO Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -1,077.05%. CARGO Therapeutics' return on equity of -45.93% beat uniQure's return on equity.
78.8% of uniQure shares are owned by institutional investors. Comparatively, 93.2% of CARGO Therapeutics shares are owned by institutional investors. 4.8% of uniQure shares are owned by company insiders. Comparatively, 2.9% of CARGO Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
uniQure has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500. Comparatively, CARGO Therapeutics has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.
uniQure currently has a consensus price target of $37.82, indicating a potential upside of 161.09%. CARGO Therapeutics has a consensus price target of $15.00, indicating a potential upside of 235.57%. Given CARGO Therapeutics' higher probable upside, analysts clearly believe CARGO Therapeutics is more favorable than uniQure.
CARGO Therapeutics has lower revenue, but higher earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than CARGO Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, uniQure had 3 more articles in the media than CARGO Therapeutics. MarketBeat recorded 3 mentions for uniQure and 0 mentions for CARGO Therapeutics. CARGO Therapeutics' average media sentiment score of 0.00 beat uniQure's score of -0.33 indicating that CARGO Therapeutics is being referred to more favorably in the news media.
Summary
uniQure and CARGO Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get CARGO Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRGX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CARGO Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CRGX) was last updated on 7/3/2025 by MarketBeat.com Staff
